首页> 外文OA文献 >The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer
【2h】

The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer

机译:Ki67,组织学等级和雌激素受体状态的组合确定了1,854名N0 / N1原发性乳腺癌未化疗女性中的低风险人群

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND: The aim was to confirm a previously defined prognostic index, combining a proliferation marker, histological grade, and estrogen receptor (ER) in different subsets of primary N0/N1 chemo-naïve breast cancer patients. METHODSDESIGN: In the present study, including 1,854 patients, Ki67 was used in the index (KiGE), since it is the generally accepted proliferation marker in clinical routine. The low KiGE-group was defined as histological grade 1 patients and grade 2 patients which were ER-positive and had low Ki67 expression. All other patients made up the high KiGE-group. The KiGE-index separated patients into two groups with different prognosis. In multivariate analysis, KiGE was significantly associated with disease-free survival, when adjusted for age at diagnosis, tumor size and adjuvant endocrine treatment (hazard ratio: 3.5, 95% confidence interval: 2.6-4.7, P<0.0001). DISCUSSION: We have confirmed a prognostic index based on a proliferation marker (Ki67), histological grade, and ER for identification of a low-risk group of patients with N0/N1 primary breast cancer. For this low-risk group constituting 57% of the patients, with a five-year distant disease-free survival of 92%, adjuvant chemotherapy will have limited effect and may be avoided.
机译:背景:目的是确定原先定义的预后指标,结合原发性N0 / N1单纯性乳腺癌患者不同亚组的增殖标志物,组织学等级和雌激素受体(ER)。方法设计:在本研究中,包括1,854例患者,Ki67被用作指标(KiGE),因为它是临床常规中公认的增殖标志物。低KiGE组被定义为ER阳性且Ki67表达低的组织学1级和2级患者。所有其他患者组成了高KiGE组。 KiGE指数将患者分为两组,预后不同。在多变量分析中,经诊断时年龄,肿瘤大小和辅助内分泌治疗调整后,KiGE与无病生存率显着相关(危险比:3.5,95%置信区间:2.6-4.7,P <0.0001)。讨论:我们已经证实了基于增殖标志物(Ki67),组织学等级和ER的预后指标,以鉴定低危人群N0 / N1原发性乳腺癌患者。对于这一占57%患者的低风险组,其五年远距离无病生存率为92%,辅助化疗的效果有限,可以避免。

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号